Webster J D, Yuzbasiyan-Gurkan V, Miller R A, Kaneene J B, Kiupel M
Comparative Medicine and Integrative Biology Program, Michigan State University, Lansing, MI 48910, USA.
Vet Pathol. 2007 May;44(3):298-308. doi: 10.1354/vp.44-3-298.
Canine cutaneous mast cell tumor (MCT) is a common neoplastic disease in dogs. Due to the prevalence of canine MCTs and the variable biologic behavior of this disease, accurate prognostication and a thorough understanding of MCT biology are critical for the treatment of this disease. The goals of this study were to evaluate and compare the utility of the proliferation markers Ki67, proliferating cell nuclear antigen (PCNA), and argyrophilic nucleolar organizing region (AgNOR) as independent prognostic markers for canine MCTs and to evaluate the use of these markers in combination, as each marker assesses different aspects of cellular proliferation. An additional goal of this study was to evaluate the associations between cellular proliferation and c-KIT mutations and between cellular proliferation and aberrant KIT protein localization in canine MCTs. Fifty-six MCTs treated with surgical excision alone were included in this study. Each MCT was evaluated for Ki67 expression, PCNA expression, and KIT protein localization using immunohistochemistry; for AgNOR counts using histochemical staining; and for the presence of internal tandem duplication c-KIT mutations using polymerase chain reaction amplification. In this study, increased Ki67 and AgNOR counts were both associated with significantly decreased survival. On the basis of these results, we recommend that the evaluation of cellular proliferation, including evaluations of both Ki67 expression and AgNORs, should be routinely used in the prognostication of canine MCTs. Additionally, the results of this study show that MCTs with aberrant KIT protein localization or internal tandem duplication c-KIT mutations are associated with increased cellular proliferation, further suggesting a role for c-KIT in the progression of canine MCTs.
犬皮肤肥大细胞瘤(MCT)是犬类常见的肿瘤性疾病。由于犬MCT的普遍性以及该疾病生物学行为的多样性,准确的预后评估和对MCT生物学的透彻理解对于该疾病的治疗至关重要。本研究的目的是评估和比较增殖标志物Ki67、增殖细胞核抗原(PCNA)和嗜银核仁组织区(AgNOR)作为犬MCT独立预后标志物的效用,并评估这些标志物联合使用的情况,因为每个标志物评估细胞增殖的不同方面。本研究的另一个目的是评估犬MCT中细胞增殖与c-KIT突变之间以及细胞增殖与异常KIT蛋白定位之间的关联。本研究纳入了56例仅接受手术切除治疗的MCT。使用免疫组织化学对每个MCT的Ki67表达、PCNA表达和KIT蛋白定位进行评估;使用组织化学染色评估AgNOR计数;使用聚合酶链反应扩增评估内部串联重复c-KIT突变的存在情况。在本研究中,Ki67和AgNOR计数增加均与生存率显著降低相关。基于这些结果,我们建议在犬MCT的预后评估中应常规使用细胞增殖评估,包括对Ki67表达和AgNORs的评估。此外,本研究结果表明,具有异常KIT蛋白定位或内部串联重复c-KIT突变的MCT与细胞增殖增加相关,进一步表明c-KIT在犬MCT进展中的作用。